We advised the initial purchasers on the offering

Davis Polk advised the representative of several initial purchasers in a Rule 144A offering by PTC Therapeutics, Inc. of $550 million aggregate principal amount of its 0.00% convertible senior notes due 2031, including $50 million aggregate principal amount of convertible notes pursuant to the exercise in full of the initial purchasers’ option to purchase additional convertible notes.

PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company’s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. PTC’S common stock is listed on the Nasdaq Global Select Market under the symbol “PTCT.”

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Yasin Keshvargar, counsel Jenna M. Godfrey and associate Alexander D. Langa. The equity derivatives team included partner Mark M. Mendez, counsel Richard Stockton Bullitt and associate Chanique C. Vassell. The intellectual property and technology team included partner David R. Bauer. The tax team included partner Lucy W. Farr and associate Omar Hersi. Members of the Davis Polk team are based in the New York and Washington D.C. offices.

Copy link to share post